VIM and prostate carcinoma: In addition, Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer [42–44], indicating that ERBB2 promotes ESCC cell migration.